Share on StockTwits

Insulet (NASDAQ:PODD) CEO Duane Desisto sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $36.30, for a total transaction of $726,000.00. Following the sale, the chief executive officer now directly owns 257,184 shares of the company’s stock, valued at approximately $9,335,779. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Canaccord Genuity cut their price target on shares of Insulet from $40.00 to $39.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $45.33.

Shares of Insulet (NASDAQ:PODD) traded down 0.14% during mid-day trading on Thursday, hitting $36.18. 221,469 shares of the company’s stock traded hands. Insulet has a one year low of $30.04 and a one year high of $51.31. The stock has a 50-day moving average of $35.84 and a 200-day moving average of $39.88. The company’s market cap is $2.022 billion.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $72.00 million for the quarter, compared to the consensus estimate of $72.94 million. During the same quarter in the prior year, the company posted ($0.20) earnings per share. The company’s quarterly revenue was up 19.8% on a year-over-year basis. On average, analysts predict that Insulet will post $-0.12 earnings per share for the current fiscal year.

Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.